Effectiveness and Safety of Korean Medicine Treatment for Cervical Disc Herniation
Observational Study on Effectiveness and Safety of Integrative Korean Medicine Treatment for Cervical Disc Herniation With Radiculopathy
1 other identifier
observational
120
1 country
1
Brief Summary
A prospective observational study investigating the effectiveness and safety of integrative Korean medicine treatment in cervical disc herniation patients with neck pain or cervical radiculopathy at 4 locations of Jaseng Hospital of Korean Medicine as assessed through of pain, functional disability, work loss and quality of life patient-reported outcomes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2019
CompletedFirst Posted
Study publicly available on registry
May 22, 2019
CompletedStudy Start
First participant enrolled
June 24, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 28, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
ExpectedDecember 17, 2025
December 1, 2025
2.6 years
May 20, 2019
December 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Numeric rating scale (NRS) out of neck pain and radiating arm pain
Change from higher score at baseline out of neck pain or radiating arm pain intensity to same score at 4 months. Total score range: -10 (worse outcome) to 10 (better outcome) Total score range: -10 (worse outcome) to 10 (better outcome)
Time Frame: Change from baseline to 4 months
Secondary Outcomes (12)
Visual analogue scale (VAS) of neck pain
Time Frame: Baseline, 2, 4, 6, 8, 12, 16, 20, 24 weeks, 1, 3, 5 years
Visual analogue scale (VAS) of radiating arm pain
Time Frame: Baseline, 2, 4, 6, 8, 12, 16, 20, 24 weeks, 1, 3, 5 years
Neck Disability Index (NDI)
Time Frame: Baseline, 2, 4, 6, 8, 12, 16, 20, 24 weeks, 1, 3, 5 years
Patient Global Impression of Change (PGIC)
Time Frame: 8, 16, 20, 24 weeks, 1, 3, 5 years
EuroQol 5-dimensions 5-levels (EQ-5D-5L)
Time Frame: Baseline, 2, 4, 6, 8, 12, 16, 20, 24 weeks, 1, 3, 5 years
- +7 more secondary outcomes
Interventions
Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
Eligibility Criteria
Patients with symptoms of neck pain or radiating arm pain alongside cervical radiculopathy symptoms
You may qualify if:
- Patients with age between 19 years \~ 65 years
- Patients with one arm pain or both side arm pain or neck pain with intensity of NRS ≥6 which occurred less then 12 month before
- Patients with cervical radiculopathy symptoms of one or both side of arms
- Patients diagnosed with cervical disc herniation with over protrusion degree of prolapsed inter-vertebral disc assessed on MRI
- Patients with plans of receiving Korean medicine treatment for cervical disc herniation for ≥2 months
- Patients who have agreed to study participation
You may not qualify if:
- Patients with other systemic diseases that may interfere with treatment effect or outcome interpretation
- Patients with soft tissue pathologies or pathologies of non-spinal origin that may cause neck pain or radiating arm pain (e.g. spinal tumor, rheumatoid arthritis)
- Patients with medical history of cervical myelopathy which can cause neck pain or radiating arm pain
- Patients with medical history of surgery in relation with cervical disc herniation
- Patients for whom acupuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anticoagulation medicine intake, serious diabetes with risk of infection, severe cardiovascular diseases, or other conditions deemed unsuitable for acupuncture treatment)
- Pregnant patients or patients planning pregnancy
- Patients with serious psychological disorders
- Patients unable to fill out study participation consent form
- Patients deemed unsuitable for study participation as assessed by the researchers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jaseng Medical Foundation
Seoul, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Won-Il Ko, KMD
Jaseng Hospital of Korean Medicine
- PRINCIPAL INVESTIGATOR
Sun-A Kim, KMD
Daejeon Jaseng Hospital of Korean Medicine
- PRINCIPAL INVESTIGATOR
Hyun-Woo Cho, KMD
Haeundae Jaseng Hospital of Korean Medicine
- PRINCIPAL INVESTIGATOR
Ji-Yun Seo, KMD
Bucheon Jaseng Hospital of Korean Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- K.M.D, Rehabilitation Medicine Specialist
Study Record Dates
First Submitted
May 20, 2019
First Posted
May 22, 2019
Study Start
June 24, 2019
Primary Completion
January 28, 2022
Study Completion (Estimated)
December 1, 2027
Last Updated
December 17, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share